The title is “Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial”. It is a phase II study in Japan commissioned by Stella Pharma and Sumitomo Heavy Industries. It is a compilation of the contents of the poster presentation at ASCO (American Society of Clinical Oncology) in 2018 and then published in the journal (Radiotherapy and Oncology) as the world’s first academic clinical trial of accelerator BNCT.
The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”
